BeOne Medicines Financials - Benzinga

BeOne Medicines Ltd

ONCNASDAQ

Trade with Public

Trade with Public

$365.00

-3.08-0.84%

In chiusura: Sep 23, 5:00 PM EST

$362.88

-2.12-0.58%

Post-mercato: 9:30 AM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

BeOne Medicines Financials

BeOne Medicines (ONC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est

BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.600 billion-$6.800 billion vs $6.479 billion estimate.

Benzinga Newsdesk

PRO
BeiGene Q2 Adj. EPS $3.84 Beats $1.44 Estimate, Sales $1.705B Beat $1.591B Estimate

BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.84 per share which beat the analyst consensus estimate of $1.44 by 166.67 percent. This is a 70.67 percent increase over earnings of $2.25 per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
BeOne Medicines Raises FY2026 Sales Guidance from $6.200B-$6.400B to $6.300B-$6.500B vs $6.369B Est.

BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.200 billion-$6.400 billion to $6.300 billion-$6.500 billion vs $6.369 billion estimate.

Benzinga Newsdesk

PRO
BeiGene Q1 Adj. EPS $3.24 Beats $0.79 Estimate, Sales $1.513B Beat $1.441B Estimate.

BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.24 per share which beat the analyst consensus estimate of $0.79 by 310.13 percent. This is a 165.57 percent increase over earnings of $1.22 per share from the same

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved